氧化应激与胰腺癌的关系

李小成; 涂经楷; 龚建平

doi:10.3969/j.issn.1001-5256.2017.10.040

氧化应激与胰腺癌的关系

DOI: 10.3969/j.issn.1001-5256.2017.10.040

1. 重庆医科大学附属第二医院肝胆外科
2. 重庆市第五人民医院普外科

详细信息

中图分类号: R735.9
计量
- 文章访问数: 2003
- HTML全文浏览量: 46
- PDF下载量: 383
- 被引次数: 0
出版历程
- 收稿日期: 2017-04-13
- 出版日期: 2017-10-20

Association between oxidative stress and pancreatic cancer

Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University

摘要

摘要: 胰腺癌早期症状不明显,发现时通常已进展至中晚期。目前晚期胰腺癌主要以化疗为主,但化疗对胰腺癌的有效率较低,给治疗带来了极大的挑战。氧化应激引起的活性氧可损伤DNA、蛋白质和脂质,并产生可改变肿瘤生物学行为的有毒和致突变的代谢产物,使该肿瘤转化为恶性表型。抗氧化剂具有抗癌的保护性作用,为抗氧化应激治疗胰腺癌的药物设计提供了基础。简述氧化应激与胰腺癌相关的分子通路研究进展,以便进一步探索靶向活性氧治疗胰腺癌的新方法。
- 胰腺肿瘤 /
- 氧化性应激 /
- 综述
Abstract: Pancreatic cancer ( PC) is often asymptomatic in the early stage and most patients have progressed to the advance stage at the time of diagnosis. At present, chemotherapy is mainly used in patients with advanced PC, but PC patients have poor response to chemotherapy, which brings great challenges to the treatment of PC. Oxidative stress-induced reactive oxygen species ( ROS) can cause damages in DNA, proteins, and lipids and produce the toxic and mutagenic metabolites that alter the biological behavior of tumor and transform the tumor into a malignant phenotype. Antioxidants have an antitumor effect and provide a basis for the design of anti-oxidative stress drugs for the treatment of PC. This article summarizes the research advances in the molecular pathways associated with oxidative stress and PC, in order to explore new ROS-targeted methods for the treatment of PC.
- pancreatic neoplasms /
- oxidative stress /
- review

HTML全文

参考文献(32)

[1]SIEGEL RL, MILLER KD, JEMAL A.Cancer Statistics, 2017[J].CA Cancer J Clin, 2017, 67 (1) :7-30.

[2]CILIBERTO D, BOTTA C, CORREALE P, et al.Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer:a meta-analysis of randomised trials[J].Eur JCancer, 2013, 49 (3) :593-603.

[3]SOSA V, MOLINE T, SOMOZA R, et al.Oxidative stress and cancer:an overview[J].Ageing Res Rev, 2013, 12 (1) :376-390.

[4]SCHIEBER M, CHANDEL NS.ROS function in redox signaling and oxidative stress[J].Curr Biol, 2014, 24 (10) :r453-r462.

[5]UCHIDA D, TAKAKI A, ISHIKAWA H, et al.Oxidative stress balance is dysregulated and represents an additional target for treating cholangiocarcinoma[J].Free Radic Res, 2016, 50 (7) :732-743.

[6]KARIN M, GRETEN FR.NF-kappa B:linking inflammation and immunity to cancer development and progression[J].Nat Rev Immunol, 2005, 5 (10) :749-759.

[7]KAMISAWA T, WOOD LD, ITOI T, et al.Pancreatic cancer[J].Lancet (London, England) , 2016, 388 (10039) :73-85.

[8]BOURSI B, FINKELMAN B, GIANTONIO BJ, et al.A clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes[J].Gastroenterology, 2017, 152 (4) :840-850, e3.

[9]ZHANG Y, YAN W, COLLINS MA, et al.Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance[J].Cancer Res, 2013, 73 (20) :6359-6374.

[10]PANG TS, CAO LP, LIN TY, et al.Multiple factor analysis of pancreatic cancer-associated risk factors[J].Chin J Pract Surg, 2014, 34 (10) :962-966. (in Chinese) 庞天舒, 曹利平, 林天宇, 等.胰腺癌相关危险因素多因素分析[J].中国实用外科杂志, 2014, 34 (10) :962-966.

[11]NARENDHIRAKANNAN RT, HANNAH MA.Oxidative stress and skin cancer:an overview[J].Indian J Clin Biochem, 2013, 28 (2) :110-115.

[12]MATSUZAWA A, ICHIJO H.Redox control of cell fate by MAP kinase:physiological roles of ASK1-MAP kinase pathway in stress signaling[J].Biochim Biophys Acta, 2008, 1780 (11) :1325-1336.

[13]NGUYEN T, NIOI P, PICKETT CB.The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress[J].J Biol Chem, 2009, 284 (20) :13291-13295.

[14]LUO Y, ZOU P, ZOU J, et al.Autophagy regulates ROS-induced cellular senescence via p21 in a p38 MAPKalpha dependent manner[J].Exp Gerontol, 2011, 46 (11) :860-867.

[15]JU KD, LIM JW, KIM KH, et al.Potential role of NADPH oxidase-mediated activation of Jak2/Stat3 and mitogen-activated protein kinases and expression of TGF-beta1 in the pathophysiology of acute pancreatitis[J].Inflamm Res, 2011, 60 (8) :791-800.

[16]CAO L, CHEN X, XIAO X, et al.Resveratrol inhibits hyperglycemia-driven ROS-induced invasion and migration of pancreatic cancer cells via suppression of the ERK and p38 MAPK signaling pathways[J].Int J Oncol, 2016, 49 (2) :735-743.

[17]LI W, CAO L, CHEN X, et al.Resveratrol inhibits hypoxia-driven ROS-induced invasive and migratory ability of pancreatic cancer cells via suppression of the Hedgehog signaling pathway[J].Oncol Rep, 2016, 35 (3) :1718-1726.

[18]ZHANG C, CAO S, TOOLE BP, et al.Cancer may be a pathway to cell survival under persistent hypoxia and elevated ROS:a model for solid-cancer initiation and early development[J].Int J Cancer, 2015, 136 (9) :2001-2011.

[19]YANG YF, TAN XD, ZHOU L, et al.Advances in the study of the relationship between MicroRNA and pancreatic cancer[J].Chin JMed Offic, 2016, 44 (11) :1203-1205. (in Chinese) 杨一帆, 谭晓冬, 周磊, 等.MicroRNA与胰腺癌关系研究进展[J].临床军医杂志, 2016, 44 (11) :1203-1205.

[20]FAVARO E, RAMACHANDRAN A, MCCORMICK R, et al.MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU[J].PLo S One, 2010, 5 (4) :e10345.

[21]WANG P, ZHU CF, MA MZ, et al.Micro-RNA-155 is induced by K-Ras oncogenic signal and promotes ROS stress in pancreatic cancer[J].Oncotarget, 2015, 6 (25) :21148-21158.

[22]VENKATARAMAN S, ALIMOVA I, FAN R, et al.MicroRNA128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence[J].PLo S One, 2010, 5 (6) :e10748.

[23]MATEESCU B, BATISTA L, CARDON M, et al.miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response[J].Nat Med, 2011, 17 (12) :1627-1635.

[24]JAJOO S, MUKHERJEA D, KAUR T, et al.Essential role of NADPH oxidase-dependent reactive oxygen species generation in regulating microRNA-21 expression and function in prostate cancer[J].Antioxid Redox Signal, 2013, 19 (16) :1863-1876.

[25]SRIDHARAN DM, ASAITHAMBY A, BAILEY SM, et al.Understanding cancer development processes after HZE-particle exposure:roles of ROS, DNA damage repair and inflammation[J].Radiat Res, 2015, 183 (1) :1-26.

[26]HOCEVAR BA, KAMENDULIS LM, PU X, et al.Contribution of environment and genetics to pancreatic cancer susceptibility[J].PLo S One, 2014, 9 (3) :e90052.

[27]HUSAIN K, CENTENO BA, CHEN D T, et al.Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-Kras G12D/+;Pdx-1-Cre mice by vitamin E delta-tocotrienol[J].Carcinogenesis, 2013, 34 (4) :858-863.

[28]CHEN Q, ESPEY MG, SUN AY, et al.Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice[J].Proc Natl Acad Sci U S A, 2008, 105 (32) :11105-11109.

[29]MONTI DA, MITCHELL E, BAZZAN AJ, et al.Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer[J].PLo S One, 2012, 7 (1) :e29794.

[30]WELSH JL, WAGNER BA, van't ERVE TJ, et al.Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN) :results from a phase Iclinical trial[J].Cancer Chemother Pharmacol, 2013, 71 (3) :765-775.

[31]SHIN SH, KIM SC, HONG SM, et al.Genetic alterations of K-ras, p53, c-erb B-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival[J].Pancreas, 2013, 42 (2) :216-222.

[32]DERAMAUDT T, RUSTGI AK.Mutant KRAS in the initiation of pancreatic cancer[J].Biochim Biophys Acta, 2005, 1756 (2) :97-101.

施引文献

资源附件(0)

访问统计